Luxempart S.A. acquired an unknown minority stake in Evariste from Montefiore Investment, SA for approximately €87 million.
November 08, 2021
Share
Luxempart S.A. (BDL:LXMPR) acquired an unknown minority stake in Evariste from Montefiore Investment, SA for approximately €87 million on November 9, 2021. Luxempart has been supported in this transaction by Hayfin, which provided debt financing package. Damien Moron of KPMG Corporate Finance France acted as financial due diligence provider, Philippe Netto of Fieldfisher France LLP acted as legal advisor, Olivier Malbos, Olivier Le Maire and Laurent Bonnin of Oddo Corporate Finance acted as financial advisor to Luxempart S.A. respectively. Jacques Ittah of Wil Consulting acted as financial advisor and Michel Turon, Paul Grandet, Anne-Laure Legout, Laëtitia Squercioni and Olivier Moriceau of UGGC & Associés acted as legal advisor to Montefiore Investment, SA.
Luxempart S.A. (BDL:LXMPR) completed the acquisition of an unknown minority stake in Evariste from Montefiore Investment, SA on November 9, 2021.
Luxempart SA is a Luxembourg-based investment company which invests in listed and private equity, as well as in private equity funds. The Company is active in Luxembourg, Belgium, France, Italy and Germany, where it manages a portfolio of listed and unlisted companies. Through Luxempart Capital Partners and Indufin Capital Partners (ICP), Luxempart also runs private equity activities. ICP is a joint-venture with the Belgian family holding Eik NV. The Company holds stakes in a number of private companies, including SES, RTL Group, Atenor, Foyer Finance, Foyer SA, SEO, PNE Wind, Pescanova, Mirato, Indufin Capital Partners - ICP Sicar, IEE, Quip, DS Care, Ekkio Capital, Thrombogenics, IP Sante domicile, Octopede Fonds private equity, among others. It also holds a majority stake in Euphaco (ABC Chemical).
LUXEMPART S.A. 
